Emmalyn Lecky
@emmalynlecky.bsky.social
PhD Candidate in Alex Toker’s lab studying cancer signaling & RNA modifications | Harvard Biological & Biomedical Sciences | UConn alum! 🐾
Reposted by Emmalyn Lecky
Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical tria...
aacrjournals.org
November 20, 2024 at 12:09 PM
Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪